Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-Month follow-up of the HIVNET 012 randomised trial

Lancet

Volumn 362, Issue 9387, 2003, Pages 859-868

  Jackson, J Brooks ^a   Musoke, Philippa ^b   Fleming, Thomas ^c,d   Guay, Laura A ^a   Bagenda, Danstan ^b   Allen, Melissa ^e   Nakabiito, Clemensia ^b   Sherman, Joseph ^a   Bakaki, Paul ^b   Owor, Maxensia ^b   Ducar, Constance ^a   Deseyve, Martina ^d   Mwatha, Anthony ^d   Emel, Lynda ^d   Duefield, Corey ^a   Mirochnick, Mark ^f   Fowler, Mary Glenn ^g   Mofenson, Lynne ^h   Miotti, Paolo ^g   Gigliotti, Maria ⁱ   Bray, Dorothy ^j   Mmiro, Francis ^b   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e FAMILY HEALTH INTERNATIONAL   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

ⁱ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^j GLAXOSMITHKLINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEVIRAPINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANEMIA; ANTIBODY DETECTION; ARTICLE; ASPHYXIA; BREAST FEEDING; BRONCHOPNEUMONIA; CLINICAL TRIAL; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEHYDRATION; DEMENTIA; DIARRHEA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EXFOLIATIVE DERMATITIS; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HEPATOMEGALY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INFECTION; JAUNDICE; KAPLAN MEIER METHOD; LABOR; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALARIA; MALE; MATERNAL HYPERTENSION; MENINGITIS; NEWBORN; NEWBORN HEMORRHAGIC DISEASE; PNEUMONIA; POLYMERASE CHAIN REACTION; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PUERPERIUM; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; RISK ASSESSMENT; SEPSIS; SEROLOGY; SIDE EFFECT; SKIN INFECTION; SUDDEN INFANT DEATH SYNDROME; SURVIVAL RATE; THRUSH; UGANDA; VERTICAL TRANSMISSION; VOMITING;

EID: 0141518673     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14341-3     Document Type: Article

References (34)

1. UNAIDS. AIDS epidemic update, December, 2002. Geneva UNAIDS-WHO, 2002. http://www.unaids.org/worldaidsday/2002/press/Epiupdate.html (accessed March 6, 2003).
2. Connor E., Sperling R., Gelber R., et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 331:1994;1173-1180.
3. Rouzioux C., Costagliola D., Burgard M., et al. Estimated timing of mother-to-child human immunodeficiency virus type 1 transmission by use of a Markov model: the HIV Infection in Newborns French Collaborative Study Group. Am J Epidemiol. 142:1995;1330-1337.
4. Bertolli J., St Louis M.E., Simonds R.J., et al. Estimating the timing of mother-to-child transmission of human immunodeficiency virus in a breast feeding population in Kinshasha, Zaire. J Infect Dis. 174:1996;722-726.
5. Wiktor S.Z., Ekpini E., Karon J.M., et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Cote d'Ivoire: a randomised trial. Lancet. 353:1999;781-785.
6. Dabis F., Msellati P., Meda N., et al. 6-month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: a double-blind placebo-controlled multicentre trial. Lancet. 353:1999;786-792.
7. Shaffer N., Chuachoowong R., Mock P.A., et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 353:1999;773-780.
8. Dunn D.T., Tess B.H., Rodrigues L.C., Ades A.E. Mother-to-child transmission of HIV: implications of variation in maternal infectivity. AIDS. 12:1998;2211-2216.
9. Leroy V., Newell M.L., Dabis F., et al. International multicentre pooled analysis of late postnatal mother-to-child transmission of HIV-1 infection. Lancet. 352:1998;597-600.
10. Miotti P.G., Taha T.E.T., Kumwenda N.I., et al. HIV transmission from breastfeeding: a study in Malawi. JAMA. 282:1999;744-749.
11. Sperling R.S., Shapiro D.E., Coombs R.W., et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. N Eng J Med. 335:1998;1621-1629.
12. Guay L., Musoke P., Fleming T., et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 354:1999;795-802.
13. O'Brien P.C., Fleming T.R. A multi-stage procedure for clinical trials. Biometrics. 35:1979;549-556.
14. Pollard R.B., Robinson P., Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 20:1998;1071-1092.
15. Sha B.E., Proia L., Kessler H.A. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 284:2000;2723-2724.
16. Benn P.D., Mercey D.E., Brink N., Scott G., William I.G. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet. 357:2001;687-688.
17. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 49:2001;1153-1156.
18. Mirochnick M., Fenton T., Gagnier P., et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. J Infect Dis. 178:1998;368-374.
19. Musoke P., Guay L., Bagenda D., et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected Ugandan women and their neonates (HIVNET 006). AIDS. 13:1999;479-486.
20. Dorenbaum A., Cunningham C.K., Gelber R.D., et al. Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial. JAMA. 288:2002;189-198.
21. Moodley D., Moodley J., Coovadia H., et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 187:2003;725-735.
22. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania,South Africa, and Uganda (Petra study): a randomised, double blind, placebo-controlled trial. Lancet. 359:2002;1178-1186.
23. Wade N.A., Birkhead G.S., Warren B. L., et al. Abbreviated Regimens of Zidovudine Prophylaxis and Perinatal Transmission of the Human Immunodeficiency Virus. N Engl J Med. 339:1998;1409-1414.
24. US Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. MMWR Morb Mortal Wkly Rep. 51:2002;1-40. http://AIDSInfo.nih.gov accessed March 6, 2003.
25. Cooper E., Charurat M., Mofenson L., et al. Effectiveness of potent antiretroviral therapies onreducing perinatal transmission of HIV-1. J Acquir Immune Defic Syndr Human Retrovirol. 29:2002;484-494.
26. Nduati R., John G., Mbori-Ngacha D., et al. Effect of breast feeding and formula feeding on transmission of HIV-1. JAMA. 283:2000;1167-1174.
27. Coutsoudis A., Pillay K., Kuhn L., et al. Method of feeding and transmission of HIV-1 from mothers to children by 15 months of age: prospective cohort study from Durban, South Africa. AIDS. 15:2001;379-387.
28. Jackson J.B., Becker-Pergola G., Guay L., et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 14:2000;F111-F115.
29. Eshleman S.H., Mracna M., Guay L.A., et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 15:2001;1951-1957.
30. Marseille E., Kahn J., Mmiro F., et al. The cost-effectiveness of a single dose nevirapine regimen to mother and infant to reduce vertical HIV transmission in Uganda. Lancet. 354:1999;803-809.
31. Joint UNAIDS/WHO Press Release. Preventing mother-to-child HIV transmission: technical experts recommend use of antiretroviral regimens beyond pilot projects. Geneva, Oct 25, 2000.
32. Sousselier M, Sousselier B, Arouko H. Protocol MPH NEV-7: prevention of the mother-to-child transmission of HIV. XIII International AIDS Conference, Durban, South Africa, July 2000: abstr LbPeC7086.
33. Stringer J.S.A., Sinkala M., Stout J.P., et al. Comparison of two strategies for administering nevirapine to prevent perinatal HIV transmission in high-prevalence, resource-poor settings. JAcquir Immune Defic Syndr. 32:2003;506-513.
34. Stringer J.S.A., Sinkala M., Chapman V., et al. Timing of the maternal drug dose and risk of perinatal HIV transmission in the setting of intrapartum and neonatal single-dose nevirapine. AIDS. 17:2003;1659-1665.